OncoMatch/Clinical Trials/NCT06420440
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
Is NCT06420440 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Lenvatinib and Tislelizumab for hcc.
Treatment: Lenvatinib · Tislelizumab · Tislelizumab — Primary liver cancer is one of the most common malignant tumors in the world, and about 80%\~90% of primary liver cancers are pathologically characterized as hepatocellular carcinoma (HCC). Radical surgery is the main method for patients with HCC to obtain long-term survival. However, the early recurrence rate of high-risk HCC is very high, which seriously affects the overall therapeutic effect.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC-A TUMOR DIAMETER MORE THAN OR EQUAL TO 5CM, BCLC-B, BCLC-C (BCLC)
Enhanced MRI determines that the tumor is technically resectable but at high risk for recurrence(BCLC-A tumor diameter more than or equal to 5cm; BCLC-B; BCLC-C) ; without distant metastasis.
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Liver function
child-pugh liver function score ≤ 7
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06420440 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage BCLC-A TUMOR DIAMETER MORE THAN OR EQUAL TO 5CM or BCLC-B or BCLC-C is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages